Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People With Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial
Higher rates of infertility, miscarriage, gestational diabetes, preeclampsia and other pregnancy complications
"In combination with diet and exercise, Wegovy is the only obesity medicine proven to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight
The triple-receptor profile makes Retatrutide relevant to research on integrated endocrine signaling
It is about compliance, comfort, side effect management, and sustainable long-term habits
Hepatic Lipid Research: Studies have reported significant effects on hepatic lipid accumulation and fat oxidation in pre-clinical models under Retatrutides GCGR activation generating strong research interest in its potential utility as a tool for studying fatty liver biology and NAFLD-related metabolic pathways
